期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

KRAS基因突变与中国结直肠癌患者预后的相关性系统评价

Prognostic value of KRAS mutations in colorectal cancer: A systematic review and meta-analysis
下载PDF
导出
摘要 目的:采用Meta分析评价KRAS基因突变在中国结直肠癌(colorectal cancer,CRC)患者预后中的作用.方法:检索电子数据库PubMed、Web of Science、Cochrane Library、万方数据库以及中国知网,搜集并纳入从建库时间至2015-04公开发表的KRAS基因突变与CRC预后相关包括总生存期(overall survival,OS)以及无进展生存期(progression free survival,PFS).应用风险比(hazard ratio,HR)和95%CI来评价结局指标.采用Stata12.0进行Meta分析.结果:本篇系统评价纳入19项研究,共计2938例患者.结果显示,KRA S突变型患者OS(HR=1.71,95%CI:1.28-2.29)和PFS(HR=2.36,95%CI:1.24-4.50)均较短,且KRAS基因12、13号密码子突变是CRC的预后的可能危险因素.结论:KRAS基因能增加中国CRC患者的死亡风险和疾病进展风险,可能是影响中国CRC患者预后的危险因素,该结论需更多的临床研究加以验证. AIM： To evaluate the prognostic significance of KRAS mutations among Chinese colorectal cancer patients METHODS： Clinical studies on the correlation between KRAS mutations and the prognosis of colorectal cancer patients were retrieved from PubMed, Web of Science, Cochrane Library, Wan Fang database and CNKI. The latest search was done in April, 2015. Both case-control studies and cohort studies were included. Hazard ratios （HRs） were used to evaluate the outcomes. Meta-analysis was performed with Stata 12.0. RESULTS： A total of 19 clinical studies with 2938 patients were qualified to this meta- analysis. Patients with KRAS mutations were associated with shorter overall survival （OS） （HR = 1.71, 95%CI： 1.28-2.29） and progression free survival （PFS） （HR = 2.36, 95%CI： 1.24-4.50）. In addition, codons 12 and 13 mutations of KRAS were related with prognosis of colorectal cancer patients. CONCLUSION： KRAS mutations are a possible risk factor for prognosis in patients with colorectal cancer. Patients with KRAS mutations show an increased risk of mortality and progression of disease. More clinical studies need to be performed to confirm our conclusion.
作者 刘佳萱 赵君 陈璐斯 马旭 代巧云 王蓓
机构地区 东南大学公卫学院环境医学工程教育部重点实验室 国家卫生计生委科学技术研究所
出处 《世界华人消化杂志》 CAS 2015年第26期4270-4278,共9页 World Chinese Journal of Digestology
基金 "十二五"国家科技支撑计划资助项目 No.2013BAI12B01~~
关键词 结直肠癌 预后 KRAS Meta分析 Colorectal cancer Prognosis KRAS Meta-analysis
分类号 R735.34 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1Rui YY, Zhang D, Zhou ZG, Wang C, Yang L, Yu YY, Chen HN. Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta- analysis and systematic review. PLoS One 2013; 8:e77901 [PMID- 24205021 DOI: 10.1371/journal. pone.0077901].
  • 2Chen J, Ye Y, Sun H, Shi G. Association between KRAS codon 13 mutations and clinical response to anti-EGFR t~eatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol 2013; 71:265-272 [PMID: 23090619 DOI: 10.1007/s00280-012-2005-9].
  • 3Guerrero S, Casanova I, Farr~ L, Mazo A, Capell~ G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000; 60:6750-6756 [PMID: 11118062].
  • 4De Roock W, Jonker DJ, Di Nicolantonio F, Sartore- Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812-1820 [PMID: 20978259 DOI: 10.1001/ jama.2010.1535].
  • 5Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Star Med 1998; 17:2815-2834 [PMID: 9921604 DOI: 10.1002/(SICI)1097-0258(19981230)17: 24<2815: : AID-SIM110>3.0.CO; 2-8].
  • 6Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16 [PMID: 17555582 DOI: 10.1186/1745-6215-8-16].
  • 7Wells GA, Shea B, O'connell D, Peterson JEA, Welch V, Losos M, Tugwell P. The Newcastle- Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. Available from: http://www.ohri.ca/programs/ clinical epidemiology/nosgen.pdf.
  • 8Accessed April 20, 2013 Ren J, Li G, Ge J, Li X, Zhao Y. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum 2012; 55:913-923 [PMID: 22810479 DOI: 10.1097/DCR.0b013e318251d8dg].
  • 9Chen ], Guo F, Shi X, Zhang L, Zhang A, Jin H, He Y. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer 2014; 14:802 [PMID: 25367198 DOh 10.1186/1471-2407-14- 802].
  • 10Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931-5937 [PMID: 19884549 DOI: 10.1200/JCO.2009.22.4295].

二级参考文献41

  • 1Allegra C J, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion : testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy [J]. J Clin Oncol, 2009, 27 (12): 2091-2096.
  • 2Rocken C. Molecular targets for colon cancer: VEGF, EGFR- and what else [ J ]. Pathologe, 2008, 29 (suppl 2) : 200-203.
  • 3Franklin WA, Haney J, Sugita M, et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer [J]. J Mol Diagn, 2010, 12(1): 43-50.
  • 4Cunningham D, Humbler Y, Siena S, et al. Cetuximab monorherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Eng J Med, 2004, 351(8) : 337-345.
  • 5Van Custem E, Mayer R J, Gold P, et al. Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal refractory to both irinotecan and oxliplatin [J]. Eur J Cancer, 2004, (supply2) : 85-86.
  • 6Piessevaux H, Buyse M, De Roock W, et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial) [J]. Ann Oncol, 2009, 20(8) : 1375-1382.
  • 7Asmis TR, Powell E, Karapetis CS, et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC):resuhs from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care [J]. Ann Oncol, 2011, 22 (1) : 118-126.
  • 8Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K- ras mutations and benefit from cetuximab in advanced colorectal cancer[J]. N Engl J Med, 2008, 359(17): 1757-1765.
  • 9Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorrectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status[J]. J Clin Oncol, 2011,29(15) : 2011-2019.
  • 10Carsten B, Igor B, Anatoly M, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer [J]. J Clin Oncol, 2009, 27(5) : 663-671.

共引文献9

世界华人消化杂志
2015年 第26期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部